Navigation Links
CEL-SCI Corporation Releases Letter to Shareholders
Date:7/7/2009

eon went from about $3 to $27 on that news. The validation of the manufacturing facility is a critical step to starting this Phase III trial.

Our Phase III trial has been designed to remove many of the common clinical trial problems. We have identified the most common reasons for Phase III study failures or failure to receive approval to sell a drug, other than the drug not working, and they are:

1. Phase III study not reviewed by FDA and not acceptable to FDA:

Our Phase III study was reviewed in detail, and we have made changes

based on FDA's comments prior to commencement of the Phase III

trial.

2. Study too small:

Our study will enroll about 800 patients, a very sizeable number.

3. Clinical endpoint not relevant:

We follow overall survival of the patients, the gold standard. The

Clinical endpoint cannot be more relevant.

4. Change in treatment protocol between Phase II and Phase III without

additional studies:

We have made no such changes. Therefore, we expect the Phase II

results to be representative of the results one can expect in the

Phase III trial.

5. Insufficient attention to manufacturing issues:

We have validated our manufacturing process and built a dedicated

manufacturing facility for Multikine.

We believe that the success of this study will open cancer therapy to a whole new way of fighting cancer, one that is not toxic and one that works with the body, not against the body. We have high confidence that this study will be successful for the following reasons:

  • All clinical indicators support the finding of increased survival in Phase II.
  • The 10% increase in overall survival needed to meet the Phas
    '/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. CEL-SCI to Present at the Noble Financial Conference
2. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
3. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
4. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
5. CEL-SCI Takes Delivery of New Manufacturing Facility
6. Updated Pictures of CEL-SCI Manufacturing Facility Available Online
7. CEL-SCI Corporation Releases Letter to Shareholders
8. CEL-SCI Corporation Announces 2008 Financial Results
9. CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products
10. CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease
11. CEL-SCIs L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... In contrast to traditional LED lights where the ... uses proprietary LED technology to incorporate their spectra in ... is critical in low proximity installations. The Valoya L-series ... lifetime which is up to four times longer than ... cost was clearly higher when compared to traditional fluorescent ...
(Date:12/19/2014)... 18, 2014 With only 2 weeks ... special on Sartorius Biohit products . The product specials ... Picus Electronic Pipette Trade-in Program, and free pipette tips. ... officers around the world. They are ideal for lab ... include:, ,     Full volume range of 0.1 ...
(Date:12/19/2014)... Egenix, Inc. is pleased to announce that ... Board, to succeed Donald Fresne ; Mr. Fresne has ... a member of the Board.  In recognition of the many ... over almost twenty years, the Board designated Mr. Fresne as ... established a Search Committee to find a suitable replacement with ...
(Date:12/19/2014)... -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company ... announced the results of its annual general meeting of ... year in Relmada,s history and it set the stage ... Sergio Traversa , chief executive officer of Relmada. "Over ... human resource and clinical development objectives that position Relmada ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2
... Sigma-Aldrich (Nasdaq:,SIAL) is pleased to announce that Patrick ... R&D for the Research Biotech business unit, effective,October ... expand Sigma-Aldrich,s,leadership position through the development of new ... been involved with Sigma-Aldrich,since 2005 as a member ...
... BIOM ),(TSX: BRA) (the "Company") today announced that, ... in the United States, it intends,to change its name ... shareholder and court approval of a plan of arrangement, ... parent corporation,of a successor corporation of the current Biomira ...
... Zimmer Holdings, Inc.,(NYSE: ZMH ; SWX: ZMH) today ... in New Jersey an ongoing federal investigation into its,financial ... settlement, Zimmer entered into a Deferred Prosecution,Agreement, will pay ... be,subject to oversight by a federal monitor appointed by ...
Cached Biology Technology:Sigma-Aldrich Names Patrick Sullivan New VP of Research and Development for Research Biotech 2Biomira announces plan to change name to Oncothyreon 2Biomira announces plan to change name to Oncothyreon 3Biomira announces plan to change name to Oncothyreon 4Biomira announces plan to change name to Oncothyreon 5Biomira announces plan to change name to Oncothyreon 6Zimmer Announces Settlement of Federal Investigation 2Zimmer Announces Settlement of Federal Investigation 3Zimmer Announces Settlement of Federal Investigation 4
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced ... the APAC Region 2015-2019"  report to their offering. ... this market is advances in technology. With continuous ... biometric solutions to the latest standard that meets ...
(Date:12/11/2014)... PAUL, Minn. , Dec. 10, 2014 /PRNewswire/ ... wireless physiologic monitoring, has released a new series ... needs of preclinical toxicology researchers. M series, part ... help toxicologists collect the best possible physiologic data ... Adding functional endpoints to toxicology studies ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical ... building for its School of Medicine. Funding for this ... capital campaign that will be publicly launched next summer. ... located in the former 60 series R.J. Reynolds Tobacco ... Quarter. Construction will begin immediately with plans to be ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... University of Minnesota invention could help make storage of ... invention was licensed to SustainX, a leading global developer ... compressed air methods to store large amounts of energy ... sources, like wind and solar, are unpredictable. The wind ...
... April 16, 2012 /PRNewswire-iReach/ -- Global Information ... in biotechnology and biomarker market research with the release ... US molecular diagnostics market, available immediately, and remaining limited ... May. The 2012 US Molecular Diagnostics ...
... Overall, 17% of children in the United States are ... as 25%. While poor diets and physical inactivity are the ... play a role. A study by Columbia University,s ... New York City exposed to higher concentrations of chemicals called ...
Cached Biology News:2012 Forecast for US Molecular Diagnostics Market Now Available From Global Information Inc. 2Prenatal exposure to air pollution linked to childhood obesity 2Prenatal exposure to air pollution linked to childhood obesity 3
Request Info...
Streptomycin sulfate an aminoglycoside used for bacterial selection binds to the small ribosomal subunit and interferes with protein biosynthesis.21H39N7O12)2x3H2SO4Formula weight:...
...
...
Biology Products: